Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 8/20 | 0.86 |
| ▸ | CSNK1E | P49674 | 10/20 | 0.69 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111059 | 0.90 | RIPK3 (0.70) | RIPK3CSNK1EHASPINCSNK1D | |
| SCHEMBL3120424 | 0.89 | CSNK1E (0.70) | RIPK3CSNK1EHASPINCSNK1D | |
| SCHEMBL3111147 | 0.89 | RIPK3 (0.69) | RIPK3CSNK1EHASPINCSNK1D | |
| SCHEMBL23515899 | 0.87 | CSNK1E (0.74) | RIPK3CSNK1EHASPIN | |
| SCHEMBL3112554 | 0.87 | RIPK3 (0.80) | RIPK3CSNK1EHASPINCSNK1DMAPK14 | |
| SCHEMBL3112847 | 0.87 | RIPK3 (0.80) | RIPK3CSNK1EHASPIN | |
| SCHEMBL3124431 | 0.87 | RIPK3 (0.67) | RIPK3CSNK1EHASPINCSNK1D | |
| SCHEMBL3116734 | 0.87 | RIPK3 (0.70) | RIPK3CSNK1EHASPINCSNK1D | |
| SCHEMBL15124386 | 0.86 | RIPK3 (0.83) | RIPK3CSNK1EHASPINCSNK1D | |
| SCHEMBL3119786 | 0.86 | CSNK1E (0.74) | RIPK3CSNK1EHASPINCSNK1DMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-06-17 | — | — | US | disclosed |
| US-10973820-B2 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-04-13 | — | — | US | disclosed |
| WO-2020249717-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2020-12-17 | — | — | WO | disclosed |
| WO-2019115711-A1 | COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2019-06-20 | — | — | WO | disclosed |
| EP-3498278-A1 | COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2019-06-19 | — | — | EP | disclosed |
| US-20190175596-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175596-A1 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | RIPK3 3485/4885CSNK1E 2897/4885HASPIN 2595/4885 |
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | RIPK3 3657/4885CSNK1E 2990/4885HASPIN 2902/4885 |
| US-10973820-B2 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | RIPK3 3485/4885CSNK1E 2897/4885HASPIN 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.